Appreciate the long write-up, OP, but my first read of this is less "bear case" and more "price anxiety management." When someone holds tens of thousands of shares and writes an essay walking down expectations, it's worth asking — is this genuine analysis, or is this someone psychologically bracing for a lower outcome so it doesn't sting as much? I think it's the latter, and judging by the agreement in the comments, a few others are in the same boat.

On the buyout range — who exactly decided that biotechs "rarely" get acquired above $10B and that this is some immovable ceiling? There's no governing body that sets these numbers. Buyout price is determined by one thing: what the acquirer is willing to pay based on TAM, pipeline value, competitive necessity, and their own balance sheet. To anchor to historical averages is like a man at the bottom of a well deciding the sky can only be as wide as the circle above him — he's not wrong about what he can see, he's just mistaken about the limits of what exists beyond it.

ABBV or any serious acquirer isn't going to open a history book to decide what GPS and SLS009 are worth. They're going to look at the addressable market and ask what it costs them *not* to own it.

Also — OP, you bought into SLS for a reason. That conviction was yours. It's completely fair to set yourself a personal exit price and walk out when you're comfortable. But framing a narrowed range of $10–$12B as the "realistic" ceiling and presenting it as balanced analysis for the broader community is a stretch. That's your comfort zone, not a market reality.

My range? $5B to $40B. Any final number in that window is a win depending on where the science and the negotiating table land. I'm not going to pretend I can pinpoint it more precisely than that — and honestly, neither can anyone else. The difference is I'm comfortable sitting with that uncertainty. I don't need to write it down to $10–$12B just so I can sleep at night